Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 6/20 | 0.65 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.65 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 3/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL56763 | 0.96 | GMNN (0.63) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL10343746 | 0.96 | ANPEP (0.61) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL802822 | 0.84 | ANPEP (0.50) | ANPEPERAP1ERAP2TSHRCYP3A4 | |
| SCHEMBL1568287 | 0.82 | — | — | |
| SCHEMBL101928 | 0.82 | — | — | |
| SCHEMBL15251619 | 0.82 | — | — | |
| SCHEMBL5027780 | 0.82 | — | — | |
| SCHEMBL14181588 | 0.82 | — | — | |
| SCHEMBL75810 | 0.82 | — | — | |
| SCHEMBL22214422 | 0.82 | ANPEP (0.48) | ANPEPERAP1ERAP2TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339567-A1 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | UNIV MUENCHEN TECH (DE) | 2025-11-06 | — | — | US | claimed |
| EP-4076541-A1 | MODIFIED GRPR ANTAGONIST PEPTIDES FOR IMAGING AND THERAPY OF CANCER | Technische Universität München (DE) | 2022-10-26 | — | — | EP | claimed |
| CN-114845742-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2022-08-02 | — | — | CN | claimed |
| EP-3841129-A1 | CHITOSAN DERIVATIVES AND METHODS FOR PREPARING THE SAME | Haskoli Islands (IS) | 2021-06-30 | — | — | EP | claimed |
| WO-2021121734-A1 | MODIFIED GRPR ANTAGONIST PEPTIDES FOR IMAGING AND THERAPY OF CANCER | Technische Universität München (DE) | 2021-06-24 | — | — | WO | claimed |
| WO-2020039463-A1 | CHITOSAN DERIVATIVES AND METHODS FOR PREPARING THE SAME | HASKOLI ISLANDS (IS) | 2020-02-27 | — | — | WO | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250339567-A1 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | UNIV MUENCHEN TECH (DE) | 2025-11-06 | — | — | US | disclosed |
| CN-120081907-A | Radiolabeled bombesin derivative compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders | 省卫生服务机构 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| EP-4076541-A1 | MODIFIED GRPR ANTAGONIST PEPTIDES FOR IMAGING AND THERAPY OF CANCER | Technische Universität München (DE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114845742-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2022-08-02 | — | — | CN | disclosed |
| US-6150519-A | MULTISTAGE PROCESS WITH BASIFICATION AND ION EXCHANGING THEN ISOLATION AN ALLENE COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-0994108-A1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
| US-5929233-A | HALOGENATION OF ALLENYL BETA-LACTAM IN PRESENCE OF SULFINATE ION OR THIOLATE ION CAPTURING AGENT | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1999-07-27 | — | — | US | disclosed |
| EP-0759436-A1 | PROCESSES FOR THE PREPARATION OF BETA-LACTAM DERIVATIVE | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-02-26 | — | — | EP | disclosed |
| EP-0441620-B1 | Production of alpha-olefin polymers | MITSUBISHI CHEM CORP (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5147839-A | Solid coordination catalyst containing hydrocarbyloxysilane and vinylalkylsilane components; stereospecific, selective | MITSUBISHI PETROCHEMICAL COMPANY LIMITED (JP) | 1992-09-15 | — | — | US | disclosed |
| EP-0441620-A2 | Production of alpha-olefin polymers | MITSUBISHI CHEMICAL CORPORATION (JP) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339567-A1 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | RXFP2, XPNPEP2, ANTXR2 | ANPEP 27/4885ERAP1 201/4885ERAP2 72/4885 |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | ANPEP 4097/4885ERAP1 3102/4885ERAP2 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.